Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01GM145723-01 | U.S. NIH Grant/Contract | View source | |
| Protocol Version 3/27/2025 | Other Identifier | UW Madison | |
| A539714 | Other Identifier | UW Madison |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of General Medical Sciences (NIGMS) | NIH |
Not provided
Not provided
Not provided
Not provided
This study investigates fluorescence image-guided surgery to allow precise identification of necrotic tissue both preoperatively and intraoperatively in burn patients. Furthermore, it uses a multi-model approach to elucidate the localization of ICG in inflammation and necrosis to determine how this novel use of a well-known fluorescence marker can be optimized to aid in surgical decision making. This proposal will provide the necessary data to support the design of a larger clinical trial to study the feasibility and efficacy of this technology to improve the precision of necrosis detection and removal and improve wound healing outcomes. Up to 100 participants will be on study for up to approximately 24 days.
Tissue necrosis is a form of cell death caused by a wide variety of diseases and injuries. Current methods of detecting tissue necrosis to guide surgical decision making are limited. In burn injury, clinical visualization of tissue necrosis is the standard of care; however, it is an imprecise method that can result in delays in care, unnecessary surgery, and removal of viable tissue. There is a critical need to identify novel methods to improve the detection of necrosis in burn injury to aid perioperative clinical decision making. While Indocyanine Green Angiography (ICGA) has been shown to identify burn depth using perfusion as a surrogate marker for necrosis, it has not been widely adopted for clinical decision making. Recently, clinical trials using delayed imaging of high dose ICG (Second Window Indocyanine Green - SWIG) have shown promise in image-guided surgical resection of tumors. The investigators propose that SWIG imaging can be employed to enhance surgical decision-making in burn injury, as well as in many disease processes involving necrosis. The knowledge gained from this project will fill the critical need to prevent unnecessary surgery, improve surgical precision, and provide insight into ICG localization in inflamed and necrotic tissue.
The goal of this project is to characterize the SWIG fluorescence in burn inflammation and necrosis on a macroscopic and microscopic level.
Cohort 1 - The investigators will characterize fluorescent signals from SWIG in the healing potential of indeterminate depth burns in humans.
Cohort 2 - The investigators will examine the association between SWIG fluorescence and depth of necrosis in surgically excised burns, and in cases where surgery is canceled due to unexpected healing, in human subjects.
This project will result in clinical data testing of ICG for direct detection of necrotic tissue using a fluorescence imaging device optimized for burn surgery, while developing a platform for quantification of tissue necrosis and characterization of ICG-avid necrosis. These studies will provide necessary data to inform the design of a larger clinical trial to determine the efficacy and validity of ICG fluorescence-guided clinical decision making to improve outcomes for burn patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aim 1: Partial Thickness Burn Wounds | Participants with 1-30% total body surface area (TBSA) partial thickness burn wounds admitted to the University of Wisconsin (UW) Burn Center within 24 hours of burn injury and expected to be admitted for 3 days. Indocyanine green angiography (ICGA) fluorescence imaging immediately after administration of 7mg of ICG, and second window indocyanine green (SWIG) fluorescence imaging ~24 hours after administration of up to 5 mg/kg ICG of human burn wounds. ICGA within 72 hours of admission with the OnLume Clinical Imaging System (CIS). SWIG fluorescence imaging will also be performed perioperatively if applicable. |
| |
| Aim 2: Deep Partial or Full Thickness Burn Wounds | Participants with 1-30% total body surface area (TBSA) deep partial or full thickness burn wounds that will likely require surgery. ICGA fluorescence imaging immediately after administration of 7mg of ICG, and second window indocyanine green (SWIG) fluorescence imaging ~24 hours after administration of up to 5 mg/kg ICG of human burn wounds. Imaging will occur with the OnLume Clinical Imaging System (CIS). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Indocyanine green (ICG) | Drug | ICG is a well, known, FDA-approved dye |
|
| Measure | Description | Time Frame |
|---|---|---|
| Signal to Background Ratio (SBR) of ICGA and SWIG Fluorescence Images | Quantitative assessment of all ICGA and SWIG fluorescence images will be achieved in part by measuring the fluorescence signal-to-background ratio (SBR). | up to 96 hours after injury (up to 4 days on study) |
| Standard Deviation of ICGA and SWIG Fluorescence Images | Quantitative assessment of all ICGA and SWIG fluorescence images will be achieved in part by measuring the fluorescence standard deviation. | up to 96 hours after injury (up to 4 days on study) |
| Spatial Pattern of ICGA and SWIG Fluorescence Images | Qualitative characterization of all ICGA and SWIG fluorescence images will be achieved by evaluating the fluorescence spatial patterns and features. | up to 96 hours after injury (up to 4 days on study) |
| Burn Surgeon Assessment of Wound Healing (Yes/No) | For Aim 1, a burn surgeon blinded to the fluorescence data will perform an assessment of complete wound healing without surgery (Yes/No) at 21 ± 3 days from burn injury. | up to 24 days from burn injury (up to 21 days on study) |
| Burn Surgeon Assessment of Graft Loss (Yes/No) | For Aim 2, a burn surgeon blinded to the fluorescence data will perform an assessment of presence or absence of graft loss (Yes/No) 14 ± 7 days after discharge following skin grafting. | up to 21 days after discharge following skin grafting (up to 31 days on study) |
| Depth of Necrotic Tissue as a Percentage of the Tissue Biopsy Thickness | sample collected up to 4 days on study |
| Measure | Description | Time Frame |
|---|---|---|
| Spatial Correlation of ICG fluorescence and Cell Necrosis and Inflammation | sample collected up to 4 days on study |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Aim 1: Human subjects with partial thickness burn wounds admitted to the UW Burn Center within 24 hours of burn injury and expected to be admitted for 3 days Aim 2: Human subjects with 1-30% total body surface area (TBSA) deep partial or full thickness burn wounds that require surgery.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Angela Gibson, MD, PHD | University of Wisconsin - Madison School of Medicine and Public Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Wisconsin | Madison | Wisconsin | 53792 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41805739 | Derived | Junak M, Garcia H, Liu A, Donahue B, Pashaj J, Zajac J, Uselmann A, Faucher L, Pogue BW, Gibson A. Evaluation of Burn Depth using Indocyanine Green: Discrepancies Between Macroscopic Visualization and the Microenvironment. Plast Reconstr Surg. 2026 Mar 10:10.1097/PRS.0000000000013011. doi: 10.1097/PRS.0000000000013011. Online ahead of print. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002056 | Burns |
| D009336 | Necrosis |
| ID | Term |
|---|---|
| D014947 | Wounds and Injuries |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D007208 | Indocyanine Green |
| ID | Term |
|---|---|
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
For Cohort 1, involving subjects with partial thickness burns, one 4 mm tissue biopsy (optional) will be collected from the center of the burn wound after SWIG imaging is performed. Optional blood draw for research purposes.
For Cohort 2, up to two biopsies, one from the center of the burn wound and the other from a secondary location also within the tissue to be excised, will be taken at the time of surgery, or on the day of planned surgery in the event surgery was canceled due to unexpected healing (optional biopsy). Optional blood draw for research purposes.
| Clinical Fluorescence Imaging Device | Device | OnLume Clinical Imaging System or Commercially-available FDA approved clinical fluorescence imaging device (SPY Elite fluorescence imaging system, SPY-PHI portable handheld imaging system, or EleVision IR platform (also known as VS3-IR system) |
|
|